Levodopa-induced dyskinesia: brain iron deposition as a new hypothesis
BioMetals · 2024
DOI: 10.1007/s10534-024-00628-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift BioMetals, 2024. Verfasst von Fanshi Zhang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Affiliated Hospital of Zunyi Medical University, No. 149, Dalian Road, Huichuan District, Zunyi City, 563000, , Guizhou Prov…. Hauptthemen laut MEDLINE: Levodopa, Iron, Brain, Parkinson Disease. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 143 Literaturangaben. Gefördert von: the Zunyi city science and technology bureau support foundation, the Collaborative Innovation Center of Chinese Ministry of Education, the Guizhou provincial "hundred" level innovative talents funds.
Abstract (Originalsprache)
Parkinson's disease (PD) is a common neurodegenerative disease in the older adults. The main pathological change in PD is the degenerative death of dopamine (DA) neurons in the midbrain substantia nigra, which causes a significant decrease in the DA content of the striatum. However, the exact etiology of this pathological change remains unclear. Genetic factors, environmental factors, aging, and oxidative stress may be involved in the degenerative death of dopaminergic neurons in PD. Pharmacological treatment using levodopa (L-DOPA) remains the main treatment for PD. Most patients with PD consuming L-DOPA for a long time usually develop levodopa-induced dyskinesia (LID) after 6.5 years of use, and LID seriously affects the quality of life and increases the risk of disability. Recently, studies have revealed that cerebral iron deposition may be involved in LID development and that iron deposition has neurotoxic effects and accelerates disease onset. However, the relationship between cerebral iron deposition and LID remains unclear. Herein, we reviewed the mechanisms by which iron deposition may be associated with LID development, which are mainly related to oxidative stress, neuroinflammation, and mitochondrial and lysosomal dysfunction. Using iron as an important target, the search and development of safe and effective brain iron scavengers, and thus the alleviation and treatment of LID, has a very important scientific and clinical value, as well as a good application prospect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Affiliated Hospital of Zunyi Medical University, No. 149, Dalian Road, Huichuan District, Zunyi City, 563000, , Guizhou Province, China.
- Department of Neurology, Guizhou Pronvincial People's Hospital, Guiyang, China.
- Department of Neurology, Affiliated Hospital of Zunyi Medical University, No. 149, Dalian Road, Huichuan District, Zunyi City, 563000, , Guizhou Province, China. 2352332385@qq.com.
- Department of Neurology, Affiliated Hospital of Zunyi Medical University, No. 149, Dalian Road, Huichuan District, Zunyi City, 563000, , Guizhou Province, China. docxzc@zmu.edu.cn.
- The Collaborative Innovation Center of Tissue Damage Repair and Regeneration Medicine of Zunyi Medical University, Zunyi, China. docxzc@zmu.edu.cn.
Förderung
- the Zunyi city science and technology bureau support foundation
- the Collaborative Innovation Center of Chinese Ministry of Education
- the Guizhou provincial "hundred" level innovative talents funds
Zitieren
APA
Zhang, F., Ye, Z., Xie, Y., Liu, M., Zhang, L., Zhang, J., & Xu, Z. (2024). Levodopa-induced dyskinesia: brain iron deposition as a new hypothesis. BioMetals. https://doi.org/10.1007/s10534-024-00628-8
Vancouver
Zhang F, Ye Z, Xie Y, Liu M, Zhang L, Zhang J, et al. Levodopa-induced dyskinesia: brain iron deposition as a new hypothesis. BioMetals. 2024. doi:10.1007/s10534-024-00628-8
BibTeX
@article{Zhang2024,
author = {Zhang, Fanshi and Ye, Zhuofan and Xie, Yuanyang and Liu, Mei and Zhang, Li and Zhang, Jun and Xu, Zucai},
title = {Levodopa-induced dyskinesia: brain iron deposition as a new hypothesis},
journal = {BioMetals},
year = {2024},
doi = {10.1007/s10534-024-00628-8}
}
EUVIMED